Cardiology Division, Arrhythmia Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114-2750, USA.
Semmelweis University, Heart and Vascular Center, Városmajor 68, 1122 Budapest, Hungary.
Europace. 2018 Mar 1;20(3):492-500. doi: 10.1093/europace/euw382.
Cardiac Resynchronization Therapy (CRT) reduces morbidity and mortality for patients with heart failure and wide QRS complex, but up to 1/3 of patients are "non-responders" to the therapy. This study examines the ability of a simple standard electrocardiogram (ECG)-based scoring system to predict clinical outcome.
Four hundred and ninety-one consecutive patients with CRT-implants (79% males, mean age 71 years, LVEF 24%, 59% with ischemic cardiomyopathy, 83% in NYHA class III) were included from a single large volume centre. All patients met standard indications for CRT, and were followed for 3 years after CRT implantation. Three ECG parameters were measured on the post-implant ECG, and compared to pre-implantation measurements: QRS duration, time to intrinsicoid deflection onset (ID) in V1 lead, amplitude change in V1 lead. Each positive ECG variable was given a numerical value of 1 to create the score (ranging 0-3). Clinical outcome was assessed as a composite of all-cause death, left ventricular assist device implantation, cardiac transplantation and HF hospitalization. Event-free survival was predicted by shortening of QRS duration ≥20 ms (HR 0.66 [95% CI 0.48-0.90] P = 0.009), ≥50% decreased summed R + S amplitude in V1 lead (HR 0.67 [0.49-0.90] P = 0.009) and ≤40 msec ID time in lead V1 during pacing (HR 0.63 [0.46-0.86] P = 0.004). The total score was an independent predictor for both event-free survival (HR 0.65 [0.54-0.77] P < 0.001) and for ≥10% left ventricular ejection fraction improvement (OR 1.7 [1.3-2.3] P < 0.001).
Composite data from 12-lead ECG during CRT-treatment can be used in a simple score to predict long-term clinical outcome.
心脏再同步治疗(CRT)可降低宽 QRS 波群心力衰竭患者的发病率和死亡率,但多达 1/3 的患者对该治疗无反应。本研究旨在评估一种简单的基于标准 12 导联心电图(ECG)评分系统预测临床结局的能力。
本研究纳入了来自单个大型中心的 491 例连续 CRT 植入患者(79%为男性,平均年龄 71 岁,LVEF 为 24%,59%为缺血性心肌病,83%为 NYHA Ⅲ级)。所有患者均符合 CRT 标准适应证,并在 CRT 植入后 3 年进行随访。在植入后心电图上测量了 3 个心电图参数,并与植入前测量值进行比较:QRS 时限、V1 导联内向初始偏转时间(ID)、V1 导联振幅变化。每个阳性心电图变量均赋值 1 分,创建评分(范围 0-3 分)。临床结局评估为全因死亡、左心室辅助装置植入、心脏移植和心力衰竭住院的复合终点。QRS 时限缩短≥20ms(HR 0.66 [95%CI 0.48-0.90],P=0.009)、V1 导联 R+S 波总振幅降低≥50%(HR 0.67 [0.49-0.90],P=0.009)和起搏时 V1 导联 ID 时间≤40ms(HR 0.63 [0.46-0.86],P=0.004)可预测无事件生存。总评分是无事件生存(HR 0.65 [0.54-0.77],P<0.001)和左心室射血分数改善≥10%(OR 1.7 [1.3-2.3],P<0.001)的独立预测因素。
CRT 治疗期间 12 导联心电图的综合数据可用于简单评分以预测长期临床结局。